Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Net Income towards Common Stockholders (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 41.68% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.2 million, a 119.26% increase, with the full-year FY2024 number at -$8.6 million, up 49.27% from a year prior.
  • Net Income towards Common Stockholders was -$1.3 million for Q3 2025 at NovaBay Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $7.7 million in Q1 2025 to a low of -$9.4 million in Q4 2023.
  • A 5-year average of -$2.3 million and a median of -$1.9 million in 2021 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: plummeted 41377.02% in 2021, then skyrocketed 313.41% in 2025.
  • NovaBay Pharmaceuticals' Net Income towards Common Stockholders stood at -$893000.0 in 2021, then plummeted by 818.92% to -$8.2 million in 2022, then decreased by 15.03% to -$9.4 million in 2023, then surged by 87.16% to -$1.2 million in 2024, then dropped by 6.68% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Net Income towards Common Stockholders are -$1.3 million (Q3 2025), -$1.9 million (Q2 2025), and $7.7 million (Q1 2025).